Bittium Corporation
Half Year financial report
Bittium Corporation's Half-Year Financial Report January-June 2025
Bittium Corporation's Stock Exchange Release on 8 August 2025, at 8.00 am
(CEST+1)
Net sales increased and the order backlog improved significantly in the first
half of the year.
Figures in parentheses refer to the corresponding period a year earlier, unless
otherwise stated.
Summary April-June 2025
· Net sales grew 15.6 percent from the previous year and were EUR 22.9 million
(EUR 19.8 million).
· Product-based net sales were EUR 15.1 million (EUR 11.9 million),
representing 66.0 percent (60.1 percent) of total net sales.
· Service-based net sales were EUR 7.8 million (EUR 7.9 million), representing
34.0 percent (39.9 percent) of total net sales.
· In the second quarter, a total of approximately EUR 0.9 million non
-recurring costs, affecting EBITDA, operating result and result for the period,
were recorded in the second quarter income statement, resulting from change
negotiations held in the Finnish company of the Medical Business Segment and
other measures aimed at streamlining operations and processes.
· EBITDA was EUR 2.9 million (EUR 4.2 million), representing 12.6 percent of
net sales (21.2 percent).
· The operating result was EUR 1.1 million (EUR 1.9 million), representing 4.9
percent of net sales (9.6 percent).
· The result for the period was EUR 1.1 million (EUR 1.6 million) and earnings
per share were EUR 0.032 (EUR 0.045).
· Cash flow from operating activities was EUR 0,0 million (EUR -2,3 million).
· Net cash flow was EUR -6,1 million (EUR -5,7 million).
· Order backlog was EUR 43,1 million (EUR 33,8 million).
· Number of personnel at the end of the period was 538 (502).
· The Annual General Meeting held on 7 May 2025 decided, in accordance with
the Board of Directors' proposal, that a dividend of EUR 0.10 per share be
distributed based on the approved balance sheet for the financial period January
1-December 31, 2024.
· Petri Toljamo started as the new CEO of Bittium Corporation on 1 April 2025.
The previous CEO, Johan Westermarck, resigned from his position on 18 February
2025.
· Niina Huikuri was appointed as Senior Vice President, Medical Business
Segment and a member of the Management Group as of 1 May 2025.
· Teemu Hannula was appointed as Vice President, Operations and a member of
the Management Group as of 1 June 2025.
· The Board of Directors of Bittium Corporation decided on a one-time
additional share program for the CEO and a new program in Bittium Corporation's
management share-based incentive system.
· As a result of the change negotiations held at Bittium Biosignals Oy, the
Finnish company of the Medical Business Segment, the company dismissed 18
employees for financial, production and operational restructuring reasons. If
the dismissals are fully implemented and other measures aimed at improving the
efficiency of operations and processes are taken the company estimates that it
will achieve annual savings of approximately EUR 2.0 million. As a result of the
decisions and measures taken, the company will record non-recurring expenses
totaling approximately EUR 0.9 million in the income statement for the second
quarter of 2025, which will burden the Medical Business Segment's operating
result in that period.
· Bittium signed a new agreement to supply ECG monitoring devices to the US
-based Boston Scientific.
· Bittium received an order from the Finnish Defence Forces for tactical
software-based radio system products and accessories, as well as a new European
customer for its tactical communication solutions.
· After the review period, Bittium and the Spanish Indra Group signed a letter
of intent regarding strategic cooperation related to tactical radio
communication solutions.
· Investments in implementing the growth strategy and delivery capability
continued.
· The global geopolitical situation is causing general uncertainty and changes
in the operating environment.
Summary January-June 2025
· Net sales were EUR 42.2 million (EUR 37.9 million, representing 11.3 percent
increase from last year.
· The share of product-based net sales was 61.4 percent (59.6 percent),
totaling to EUR 25.9 million (EUR 22.6 million).
· The share of service-based net sales was 38.6 percent (40.4 percent),
totaling to EUR 16.3 million (EUR 15.3 million).
· In the second quarter, a total of approximately EUR 0.9 million non
-recurring costs, affecting EBITDA, operating result and result for the period,
were recorded in the second quarter income statement, resulting from change
negotiations held in the Finnish company of the Medical Business Segment and
other measures aimed at streamlining operations and processes.
· EBITDA was EUR 4.8 million (EUR 7.4 million).
· Operating result was EUR 1.5 million (EUR 2.9 million), representing 3.6
percent of net sales (7.7 percent).
· Result of the period was EUR 1.5 million (EUR 2.3 million) and earnings per
share were EUR 0.043 (EUR 0.064 ).
· Operating cash flow was EUR 9.2 million (EUR 3.0 million).
· Net cash flow was EUR 0.0 million (EUR -2.8 million).
· Order backlog was EUR 43.1 million (EUR 33.8 million).
· Personnel at the end of the period was 538 (502).
GROUP (MEUR) 2Q/2025 2Q/2024 1H/2025 1H/2024
3 months 3 months 6 months 6 months
Net sales 22.9 19.8 42.2 37.9
Change of net sales. % 15.6 % -4.4 % 11.3 % 6.5 %
EBITDA 2.9 4.2 4.8 7.4
EBITDA, % of net sales 12.6 % 21.2 % 11.4 % 19.5 %
Operating profit / loss 1.1 1.9 1.5 2.9
Operating profit / loss, % of net sales 4.9 % 9.6 % 3.6 % 7.7 %
Result of the period 1.1 1.6 1.5 2.3
Cash and other liquid assets 21.7 5.5 21.7 5.5
Equity ratio (%) 70.7 % 70.3 % 70.7 % 70.3 %
Earnings per share (EUR) 0.032 0.045 0.043 0.064
Bittium's CEO Petri Toljamo
Net sales for the second quarter of 2025 increased by 15.6 percent year-on-year
to EUR 22,9 million. The growth was mainly driven by the Defense & Security
Business Segment. Net sales in the Medical and Engineering Services Business
Segments also increased slightly. The operating result for the second quarter
was EUR 1.1 million, which corresponds to 4.9 percent of net sales. The
operating result was impacted by investments made to enable future growth and
non-recurring costs of EUR 0.9 million due to change negotiations held in the
Finnish company of the Medical Business Segment and other measures aimed at
improving the efficiency of operations and processes. The order backlog
increased by 27.5 percent year-on-year to EUR 43.1 million.
Net sales for the first half of the year increased by 11.3 percent from the
previous year and were EUR 42.2 million. The increase in net sales was mainly
generated in the Defense & Security Business Segment. Net sales in the
Engineering Services Business Segment increased slightly from the previous year.
Medical Business Segment's net sales fell slightly from the previous year due to
the exceptionally high net sales in the comparison period. Operating profit for
the first half of the year was EUR 1.5 million, corresponding to 3.6 percent of
net sales. The accumulation of operating profit was affected by investments in
future growth and non-recurring costs recorded in the second quarter.
We continued to invest in accelerating international sales and in increasing
customer focus across the organization. Our efforts are reflected in, among
other things, a significant increase in the order book, especially in the
Defense & Security Business Segment. We have renewed our organization to ensure
the right capabilities to execute our strategy across all Business Segments. We
established a subsidiary in London. A local presence in United Kingdom
strengthens our position in tenders and supports our collaboration with our
partner BAE Systems, a global defense industry operator.
We have continued to invest in strengthening our production capabilities and
scalability. We are aiming for significant international growth and production
scalability is key to building growth for us. We have, among other things,
strengthened our organization, increased production testing capacity and
expanded the number of potential manufacturing partners.
Each Business Segment has its own growth strategy. Common themes for all are
developing international sales, renewing the offering and improving operational
efficiency. We will update our growth strategy in the autumn and share more
about the company's operations, market developments and long-term growth
opportunities at the Capital Markets Day on 23 September 2025.
In the Defense & Security Business Segment, our demand is driven by the
continued growth of the defense market due to increased defense funds. Our
international customer portfolio expanded when we received an order for tactical
radios from a new European country. The products ordered are being used for
trial use by the special forces of the country's defense forces. After the
review period, we signed a letter of intent with the Spanish defense industry
operator Indra Group to start a strategic cooperation in the field of tactical
software-defined radios. Indra is a familiar partner to us from the European
ESSOR waveform development consortium.
Cooperation with the Finnish Defence Forces continued strong in the
implementation of the Partnership Agreement, and product deliveries of tactical
communication system products and radios have continued as planned. We
demonstrated a future hybrid network to the Defence Forces in cooperation with
Nokia, where several 4G/5G bubbles were connected to our tactical communication
network, enabling communication also with other authorities within the tactical
network.
We expanded our tactical service portfolio with lifecycle services for our
systems and products. A comprehensive range of lifecycle services for our
tactical communication solutions enables training for defense sector customers,
local maintenance and repair capabilities, and maximizes the operational runtime
and performance of existing tactical communication solutions. Especially in
military crisis situations, carrying out maintenance and repair measures locally
is of great importance.
We will continue to strongly enhance international sales in order to be able to
seize growth opportunities, especially in the European market. In addition, we
will continue to invest in the scalability of production and delivery
capabilities.
In the Medical Business Segment, we have not been able to grow our business
despite operating in a growing market. We have taken measures to improve the
situation and continue to work systematically to renew our product portfolio and
increase our customer portfolio and market shares.
We have continued to renew our organization so that we have the right
capabilities to implement our growth strategy. We held change negotiations in
our Medical Business Segment's Finnish Company, as a result of which we laid off
18 employees. We are now focusing on reorganizing the segment and increasing
industry expertise and focusing product development to strengthen
competitiveness. The sales focus is on commercially competitive products and
those market areas where growth enablers such as reimbursability and clinical
practices, support success.
The cooperation with our significant customer Boston Scientific Cardiac
Diagnostics strengthened and we signed a new agreement for the supply of ECG
monitoring devices for the next three years. The total value of the new
agreement is approximately USD 30-45 million, depending on the final order
volumes. Our collaboration will also continue in the development of customized
ECG technologies.
As the population ages, the most common arrhythmias, such as atrial
fibrillation, are increasing significantly. Atrial fibrillation accounts for
almost 70 percent of all arrhythmias, making it the most significant growth
driver in the ECG diagnostics market. As atrial fibrillation becomes more
common, the demand for ECG monitoring devices is also increasing, and we will
focus our sales and product development efforts significantly on this product
area in the coming years.
We have continued our sales efforts for the Respiro, used for diagnosing sleep
apnea, in the European market and delivered small quantities of devices to our
customers for commercial use. Our measuring device is particularly suitable for
diagnosing obstructive sleep apnea, the prevalence of which has increased
significantly. Today, 30 percent of the elderly suffer from sleep apnea, and the
market for home sleep apnea monitoring devices is expected to grow in the
future. We are now focusing on building sales channels and selecting strategic
partners for the commercialization of Respiro.
We will continue to improve the competitiveness of our products and focus our
operations on developing products and services that will bring us business in
the near future. Our goal is to grow profitable international business. We will
refine our strategy for the Medical Business Segment during the autumn.
In the Engineering Services Business Segment, co-operation with our customers
continued well and we received follow-up orders for existing projects. The
demand for R&D services has been affected by changes caused by geopolitical
uncertainty for some time now and we do not expect the situation to change
during the current year. Despite this, we managed to open new customer accounts,
for example from the manufacturing industry markets, and the number of new
orders increased significantly in the second quarter of the year. In line with
our strategy, we also progressed in the defense industry markets and won our
first development projects.
Earlier this year, we told about a customer project in which we were involved in
designing a prototype of a next-generation satellite terminal. The project
continued in the second quarter of the year when we received an order for the
next development phase, which will enable direct satellite connection to mobile
devices. The solution allows ordinary smartphones to establish a direct
connection to satellites for, for example, text messages, chat, voice and email.
The 3GPP-standardized 5G NTN technology used in the satellite terminal enables a
major change in the satellite communications segment, enabling mainstream
technological solutions for both the network and terminal side. This change can
bring new players into the market, also expanding our customer potential.
Outlook for 2025 (Unchanged)
Bittium expects the net sales in 2025 to be EUR 95 - 105 million (EUR 85.2
million in 2024) and the operating result to be EUR 10 - 13 million (EUR 8.6
million in 2024).
More information about Bittium's market outlook is presented in this report
under the chapter describing the development of the Business Segments, as well
as on the company's internet pages at www.bittium.com.
Invitation to a Press Conference
Bittium will organize a webcast of the half-year report for the press, analysts
and institutional investors on Friday, 8 August 2025 at 9:00 am. The conference
will be held in English.
Link to the webcast: https://bittium.videosync.fi/q2-2025
Recording the webcast and the presentation will be available after the
conference on Bittium's website at www.bittium.com/investors.
In Oulu, Finland, 8 August 2025
Bittium Corporation
The Board of Directors
Further Information:
Petri Toljamo
CEO
Tel. +358 40 344 2789 (group communications)
Karoliina Malmi
Vice President, Communications & Sustainability
Tel. +358 40 344 2789
Distribution
NASDAQ Helsinki
Main media
Bittium
Bittium specializes in the development of reliable, secure communications and
connectivity solutions leveraging its 40-year legacy of expertise in advanced
radio communication technologies. Bittium provides innovative products and
services, customized solutions based on its product platforms and R&D services.
Complementing its communications and connectivity solutions, Bittium offers
proven information security solutions for mobile devices and portable computers.
Bittium also provides healthcare technology products and services for biosignal
measuring in the areas of cardiology and neurophysiology. Net sales in 2024 were
EUR 85.2 million and operating profit EUR 8.6 million. Bittium is listed on
Nasdaq Helsinki. www.bittium.com